1. CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models. (October 2020) Authors: Liu, B.; Shen, J.; Yu, W.; Jing, C.; Saha, S.; Rangan, V.; Richardson, J.; Liu, Y.; Boule, S.; Lucas, J.; Ab, O.; Hicks, S.; Belvin, M.; Kavanaugh, M.; Schleyer, S. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preclinical evaluation of M-DGN549, a folate receptor alpha-targeting antibody–drug conjugate (ADC) with a DNA-alkylating payload. (December 2016) Authors: Setiady, Y.; Lanieri, L.; Ab, O.; Maloney, E.; Hong, E.; Qiu, Q.; Zhou, Y.; Zhao, J.; Themeles, M.; Zhang, X.; Pinkas, J.; Ruiz Soto, R.; Ponte, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗